首页|血清HE4、ROMA值联合CA724检测在CA125阴性卵巢癌中的诊断价值

血清HE4、ROMA值联合CA724检测在CA125阴性卵巢癌中的诊断价值

扫码查看
目的 分析血清人附睾蛋白4(HE4)、卵巢恶性肿瘤风险预测模型(ROMA)值联合糖类抗原CA724(CA724)检测在糖类抗原125(CA125)阴性卵巢癌中的诊断价值.方法 选取2022年1月至2022年6月于临沂市肿瘤医院就诊的卵巢癌患者共159例为研究对象,所有患者均经血清CA125检测;依据检测阴、阳性标准:CA125>35 U/mL为阳性,CA125≤35 U/mL为阴性,分为CA125阴性卵巢癌组84例和CA125阳性卵巢癌组75例.对比两组血清CA724、HE4水平和ROMA指数;分析血清CA724、HE4水平和ROMA指数单独及联合检测CA125阴性卵巢癌的诊断效能;对比CA125阴性卵巢癌组不同分期血清CA724、HE4水平和ROMA指数;分析血清CA724、HE4水平和ROMA指数三者之间的相关性.结果 CA125阳性组患者血清CA724、HE4水平和ROMA指数均比CA125阴性组低,差异有统计学意义(P<0.05);CA724、HE4、ROMA指数联合诊断CA125阴性卵巢癌患者灵敏度、特异度、准确度分别为92.73%、89.66%、91.67%,均高于三者单独检测(P<0.05);CA125阴性卵巢癌组Ⅲ~Ⅳ期患者血清CA724、HE4水平和ROMA指数均显著高于Ⅰ~Ⅱ期患者,差异有统计学意义(P<0.05);Pearson相关性分析所示,血清CA724和HE4水平呈正相关(r=0.932,P<0.001);血清CA724和ROMA指数呈正相关(r=0.749,P<0.001);血清HE4和ROMA指数呈正相关(r=0.814,P<0.001).结论 血清HE4、CA724、ROMA值可成为诊断CA125阴性卵巢癌患者的辅助检查,三指标可进一步判断卵巢癌分期,为患者诊断与治疗提供有效参考价值.
Diagnostic value of serum HE4,ROMA value combined with CA724 detection in CA125-negative ovarian cancer
Objective To analyze the diagnostic value of serum human epididymal protein 4 (HE4),ovarian malignant tumor risk prediction model(ROMA)value combined with carbohydrate antigen CA724(CA724)detection in carbohydrate antigen 125(CA125)-negative ovarian cancer. Methods A total of 159 patients with ovarian cancer who were treated at Linyi Cancer Hospital from January 2022 to June 2022 were selected as the study subjects. All patients were tested using serum CA125. The criteria for determining negative and positive results were as follows:CA125>35 U/mL was considered positive,while CA125≤ 35 U/mL was considered negative. The study included 84 cases of CA125-negative ovarian cancer and 75 cases of CA125-positive ovarian cancer. The levels of serum CA724,HE4 and ROMA index were compared between the two groups. The diagnostic efficacy of serum CA724,HE4 and ROMA index individually and combined, in detecting the CA125-negative ovarian cancer group was analyzed. Additionally,the levels of serum CA724, HE4 and ROMA index in different stages of the CA125-negative ovarian cancer group were compared. The correlation between serum CA724,HE4 levels and ROMA index was analyzed. Results The serum levels of CA724,HE4 and ROMA index in the CA125-positive group were lower than those in the CA125-negative group,and the difference was statistically significant(P<0.05). The sensitivity,specificity and accuracy of the combined diagnosis of CA724,HE4 and ROMA index in patients with CA125-negative ovarian cancer were 92.73%,89.66% and 91.67%,respectively,which were higher than those of the three tests alone(P<0.05). The levels of serum CA724,HE4 and ROMA index in stage Ⅲ-Ⅳ patients of the CA125-negative ovarian cancer group were significantly higher than those in stage Ⅰ-Ⅱ patients,and the difference was statistically significant(P<0.05). Pearson correlation analysis showed that,the serum CA724 and HE4 levels were positively correlated (r=0.932,P<0.001). Serum CA724 was positively correlated with the ROMA index (r=0.749,P<0.001). Serum HE4 and the ROMA index were positively correlated(r=0.814,P<0.001). Conclusion The Serum HE4,CA724,and ROMA values can be used as auxiliary examinations to diagnose patients with CA125-negative ovarian cancer. These three indicators can also determine the staging of ovarian cance. This provides an effective reference value for patient diagnosis and treatment.

HE4ROMACA724CA125Ovarian cancer

李晓红、赵美素、李国福

展开 >

临沂市肿瘤医院妇科,山东,临沂276000

昭通市第一人民医院妇科,云南,昭通 657000

HE4 ROMA CA724 CA125 卵巢癌

临沂市科技发展计划

2022YX0054

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(2)
  • 19